---
figid: PMC3695632__nihms286297f3
figtitle: 'Case 19-2010: A 35-Year-Old Man with Adenocarcinoma of the Cecum'
organisms:
- Homo sapiens
- Diaporthe sclerotioides
- NA
organisms_ner:
- Homo sapiens
- Drosophila melanogaster
pmcid: PMC3695632
filename: nihms286297f3.jpg
figlink: /pmc/articles/PMC3695632/figure/F3/
number: F3
caption: In a subgroup of cancers harboring wild-type KRAS (left), a specific receptor
  tyrosine kinase (RTK) (e.g., epidermal growth factor receptor [EGFR]) controls the
  PI3K–AKT and MEK–ERK signaling pathways, which are down-regulated by RTK inhibition.,
  Cancers with mutant KRAS (right) have constitutive activation of the MEK–ERK pathway
  (and possibly the PI3K–AKT pathway). Therefore, these signaling pathways are not
  down-regulated in response to RTK inhibitors. Arrows indicate activation, dead-end
  lines ( ) inhibition, and dashed lines uncertainty about the signaling connection.
  BAD denotes B-cell lymphoma 2 (BCL2)–associated agonist of cell death, BIM BCL2-interacting
  mediator of cell death, ERK extracellular-signal–regulated kinase, GDP guanosine
  diphosphate, GTP guanosine triphosphate, Mcl-1 myeloid-cell leukemia sequence 1,
  MEK mitogen-activated protein–extracellular-signal–regulated kinase, mTOR mammalian
  target of rapamycin, P phosphorylation, PDK phosphoinositide-dependent protein kinase
  1, PIP2 phosphatidylinositol 4,5-bisphosphonate, PIP3 phosphatidylinositol 3,4,5-triphosphate,
  PI3K phosphatidylinositol 3-kinase, PRAS40 AKT1 substrate 1, and RSK ribosomal protein
  S6 kinase. Asterisks indicate activating mutations.
papertitle: 'Case 19-2010: A 35-Year-Old Man with Adenocarcinoma of the Cecum.'
reftext: David P. Ryan, et al. N Engl J Med. ;362(25):2411-2419.
year: ''
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.975454
figid_alias: PMC3695632__F3
figtype: Figure
redirect_from: /figures/PMC3695632__F3
ndex: baeaf975-dec0-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3695632__nihms286297f3.html
  '@type': Dataset
  description: In a subgroup of cancers harboring wild-type KRAS (left), a specific
    receptor tyrosine kinase (RTK) (e.g., epidermal growth factor receptor [EGFR])
    controls the PI3K–AKT and MEK–ERK signaling pathways, which are down-regulated
    by RTK inhibition., Cancers with mutant KRAS (right) have constitutive activation
    of the MEK–ERK pathway (and possibly the PI3K–AKT pathway). Therefore, these signaling
    pathways are not down-regulated in response to RTK inhibitors. Arrows indicate
    activation, dead-end lines ( ) inhibition, and dashed lines uncertainty about
    the signaling connection. BAD denotes B-cell lymphoma 2 (BCL2)–associated agonist
    of cell death, BIM BCL2-interacting mediator of cell death, ERK extracellular-signal–regulated
    kinase, GDP guanosine diphosphate, GTP guanosine triphosphate, Mcl-1 myeloid-cell
    leukemia sequence 1, MEK mitogen-activated protein–extracellular-signal–regulated
    kinase, mTOR mammalian target of rapamycin, P phosphorylation, PDK phosphoinositide-dependent
    protein kinase 1, PIP2 phosphatidylinositol 4,5-bisphosphonate, PIP3 phosphatidylinositol
    3,4,5-triphosphate, PI3K phosphatidylinositol 3-kinase, PRAS40 AKT1 substrate
    1, and RSK ribosomal protein S6 kinase. Asterisks indicate activating mutations.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - EGFR
  - KRAS
  - HRAS
  - NRAS
  - GRB2
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - XYLT2
  - SOS1
  - SOS2
  - PDK1
  - PDPK1
  - AKT1
  - AKT2
  - AKT3
  - MTG1
  - RICTOR
  - MTOR
  - CRTC2
  - MDM2
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - TP53
  - TP63
  - TP73
  - GSK3A
  - GSK3B
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - MYC
  - CCND1
  - BCL2L11
  - FOXO1
  - FOXO3
  - FOXO4
  - FOXO6
  - EPHB2
  - MAPK1
  - MAPK3
  - BAD
  - IFI27
  - PSMD9
  - ZNRD2
  - DCTN6
  - TMED7
  - H3P23
  - MCL1
  - LRP8
  - AKT1S1
  - RPS6KA1
  - RPS6KA2
  - RPS6KA3
  - RPS6KA4
  - RPS6KA5
  - RPS6KA6
  - RPS6KB1
  - RPS6KB2
  - EPHB1
  - KCNH8
  - OGDH
  - Egfr
  - ras
  - Ras64B
  - Ras85D
  - drk
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Sos
  - Pdk1
  - Akt
  - rictor
  - Mtor
  - Tor
  - Crtc
  - Raf
  - p53
  - betaTub60D
  - hth
  - sgg
  - Dsor1
  - Mtk
  - Myc
  - foxo
  - Erk7
  - rl
  - cass
  - DCTN6-p27
  - dap
  - CG9588
  - PRAS40
  - raptor
  - S6kII
  - Elk
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
---
